Acute myocardial infarction initiates a cascade of events including loss of protein homeostasis and chronic inflammation that affect overall cellular repair and senescence. This contributes to loss of cardiomyocytes a...Acute myocardial infarction initiates a cascade of events including loss of protein homeostasis and chronic inflammation that affect overall cellular repair and senescence. This contributes to loss of cardiomyocytes and consequent formation of fibrotic scar. In certain vertebrate species, the heart can completely self-repair or regenerate after myocardial injury;however, this does not appear to be the case for humans. Despite this limitation, studies using novel non-pharmacologic interventions designed to protect against ischemic damage and to improve patient outcomes are ongoing. Remote ischemic conditioning stratagems are used to attenuate ischemia-reperfusion injury in clinical and animal studies;endogenous protective factors that stimulate complex signal transduction pathways are deemed responsible. Some of these factors could conceivably act in concert with those involved in regulating cardiovascular regeneration. Numerous studies have focused on cardiac regenerative interventions using stem-cell based therapies and transplantation of cardiomyocyte (or other cell types) or biocompatible matrices. This review discusses recent progress of pre-clinical and clinical translational studies for cardiac regeneration. In addition, we submit that interventions using cellular adjunctive therapies combined with remote ischemic conditioning may prove to be of interest in the battle to find novel strategies for protection against cardiac injury.展开更多
Myocardial infarction is a major cause of death and disability worldwide and myocardial infarct size is a major determinant of prognosis. Early and successful restoration of myocardial reperfusion following an ischemi...Myocardial infarction is a major cause of death and disability worldwide and myocardial infarct size is a major determinant of prognosis. Early and successful restoration of myocardial reperfusion following an ischemic event is the most effective strategy to reduce final infarct size and improve clinical outcome,but reperfusion may induce further myocardial damage itself. Development of adjunctive therapies to limit myocardial reperfusion injury beyond opening of the coronary artery gains increasing attention. A vast number of experimental studies have shown cardioprotective effects of ischemic and pharmacological conditioning,but despite decades of research,the translation into clinical effects has been challenging. Recently published clinical studies,however,prompt optimism as novel techniques allow for improved clinical applicability. Cyclosporine A,the GLP-1 analogue exenatide and rapid cooling by endovascular infusion of cold saline all reduce infarct size and may confer clinical benefit for patients admitted with acute myocardial infarcts. Equally promising,three follow-up studies of the effect of remote ischemic conditioning(RIC) show clinical prognostic benefit in patients undergoing coronary surgery and percutaneous coronary intervention. The discovery that RIC canbe performed noninvasively using a blood pressure cuff on the upper arm to induce brief episodes of limb ischemia and reperfusion has facilitated the translation of RIC into the clinical arena. This review focus on novel advances in adjunctive therapies in relation to acute and elective coronary procedures.展开更多
Background Acute myocardial infarction （AMI） is the most serious type of coronary heart disease. However, less than 30% of these patients have been treated effectively in China. Delayed treatment is a leading cause....Background Acute myocardial infarction （AMI） is the most serious type of coronary heart disease. However, less than 30% of these patients have been treated effectively in China. Delayed treatment is a leading cause. This study aimed to evaluate a new regional cooperative model for improving the first medical contact-to-device time and the therapeutic effects on AMI patients. Methods A retrospective analysis of 458 ST-elevation myocardial infarction （STEMI） patients was performed. Patients were divided into two groups in terms of before or after the model were implemented. First medical contact-to-device time （FMC2D）, Door to device time （D2D）, referral time, cardiac functions, mean cost, days of hospitalization, and major adverse cardiac events （MACE） were analyzed. Results The mean FMC2D time, D2D time and referral time of the model group were significantly lower than the control group. The left ventricular ejection fraction of the model group increased but the left ventricular end-diastolic dimension decreased compared with the control group at 6 months after discharge. These re- sults also showed that mean costs and days of hospitalization were reduced. The MACE rate was reduced in the model group. Conclusions These results suggested that the new model decreased the FMC2D time, which could improve the cardiac function and therapeutic effect of STEMI patients as well as decreased the financial burden.展开更多
目的探讨尼可地尔联合远程缺血后适应(RIPostC)对急性ST段抬高型心肌梗死(STEMI)急诊经皮冠状动脉介入(PCI)的心肌保护作用。方法单中心、前瞻性、随机对照研究。连续纳入2018年1月至2021年9月在新乡医学院附属焦作市人民医院心内科病...目的探讨尼可地尔联合远程缺血后适应(RIPostC)对急性ST段抬高型心肌梗死(STEMI)急诊经皮冠状动脉介入(PCI)的心肌保护作用。方法单中心、前瞻性、随机对照研究。连续纳入2018年1月至2021年9月在新乡医学院附属焦作市人民医院心内科病房接受PCI治疗的STEMI患者208例。按随机数字表法分为4组:A组(52例):常规PCI;B组(52例):RIPostC+常规PCI;C组(52例):尼可地尔+常规PCI;D组(52例):RIPostC+尼可地尔+常规PCI。于PCI术前后检测心肌灌注、心律失常、炎症反应、血管内皮功能、心肌损伤及心功能指标;记录术后12个月内主要不良心血管事件(MACE,包括再发心肌梗死、再发心力衰竭、心原性休克和心原性死亡)。结果(1)D组PCI术后即刻校正的TIMI血流帧数计数(CTFC)、术后24 h Curtis-Walker评分及恶性心律失常发生率均低于A组,术后2 h ST段回落幅度高于A组(均为P<0.01);(2)PCI术后48 h,D组的高敏C反应蛋白(hs-CRP)、白细胞介素6(IL-6)、丙二醛(MDA)和血管内皮生长因子(VEGF)水平均低于A、B和C组,超氧化物歧化酶(SOD)和一氧化氮(NO)水平均高于A、B和C组(均为P<0.001);B、C组的hs-CRP、IL-6、MDA和VEGF水平均低于A组,SOD和NO水平均高于A组(均为P<0.001);(3)PCI术后12 h和48 h,D组的高敏心肌肌钙蛋白I(hs-cTnI)水平均低于A、B和C组,B、C组的hs-cTnI水平均低于A组(均为P<0.001);(4)PCI术后1个月和12个月,D组的左心室射血分数(LVEF)水平均高于A、B和C组,B、C组的LVEF水平均高于A组(均为P<0.001);(5)PCI术后12个月内,4组患者的MACE发生率无统计学差异(χ^(2)=4.396,P=0.22)。结论单纯尼可地尔或RIPostC在PCI中均具有改善心肌灌注、拮抗氧化应激、抑制炎症反应、改善血管内皮、保护心肌细胞和改善心功能等作用,尼可地尔联合RIPostC的心肌保护作用明显优于单纯尼可地尔或RIPostC,联用具有协同、叠加效果。展开更多
文摘Acute myocardial infarction initiates a cascade of events including loss of protein homeostasis and chronic inflammation that affect overall cellular repair and senescence. This contributes to loss of cardiomyocytes and consequent formation of fibrotic scar. In certain vertebrate species, the heart can completely self-repair or regenerate after myocardial injury;however, this does not appear to be the case for humans. Despite this limitation, studies using novel non-pharmacologic interventions designed to protect against ischemic damage and to improve patient outcomes are ongoing. Remote ischemic conditioning stratagems are used to attenuate ischemia-reperfusion injury in clinical and animal studies;endogenous protective factors that stimulate complex signal transduction pathways are deemed responsible. Some of these factors could conceivably act in concert with those involved in regulating cardiovascular regeneration. Numerous studies have focused on cardiac regenerative interventions using stem-cell based therapies and transplantation of cardiomyocyte (or other cell types) or biocompatible matrices. This review discusses recent progress of pre-clinical and clinical translational studies for cardiac regeneration. In addition, we submit that interventions using cellular adjunctive therapies combined with remote ischemic conditioning may prove to be of interest in the battle to find novel strategies for protection against cardiac injury.
文摘Myocardial infarction is a major cause of death and disability worldwide and myocardial infarct size is a major determinant of prognosis. Early and successful restoration of myocardial reperfusion following an ischemic event is the most effective strategy to reduce final infarct size and improve clinical outcome,but reperfusion may induce further myocardial damage itself. Development of adjunctive therapies to limit myocardial reperfusion injury beyond opening of the coronary artery gains increasing attention. A vast number of experimental studies have shown cardioprotective effects of ischemic and pharmacological conditioning,but despite decades of research,the translation into clinical effects has been challenging. Recently published clinical studies,however,prompt optimism as novel techniques allow for improved clinical applicability. Cyclosporine A,the GLP-1 analogue exenatide and rapid cooling by endovascular infusion of cold saline all reduce infarct size and may confer clinical benefit for patients admitted with acute myocardial infarcts. Equally promising,three follow-up studies of the effect of remote ischemic conditioning(RIC) show clinical prognostic benefit in patients undergoing coronary surgery and percutaneous coronary intervention. The discovery that RIC canbe performed noninvasively using a blood pressure cuff on the upper arm to induce brief episodes of limb ischemia and reperfusion has facilitated the translation of RIC into the clinical arena. This review focus on novel advances in adjunctive therapies in relation to acute and elective coronary procedures.
文摘Background Acute myocardial infarction （AMI） is the most serious type of coronary heart disease. However, less than 30% of these patients have been treated effectively in China. Delayed treatment is a leading cause. This study aimed to evaluate a new regional cooperative model for improving the first medical contact-to-device time and the therapeutic effects on AMI patients. Methods A retrospective analysis of 458 ST-elevation myocardial infarction （STEMI） patients was performed. Patients were divided into two groups in terms of before or after the model were implemented. First medical contact-to-device time （FMC2D）, Door to device time （D2D）, referral time, cardiac functions, mean cost, days of hospitalization, and major adverse cardiac events （MACE） were analyzed. Results The mean FMC2D time, D2D time and referral time of the model group were significantly lower than the control group. The left ventricular ejection fraction of the model group increased but the left ventricular end-diastolic dimension decreased compared with the control group at 6 months after discharge. These re- sults also showed that mean costs and days of hospitalization were reduced. The MACE rate was reduced in the model group. Conclusions These results suggested that the new model decreased the FMC2D time, which could improve the cardiac function and therapeutic effect of STEMI patients as well as decreased the financial burden.
文摘目的探讨尼可地尔联合远程缺血后适应(RIPostC)对急性ST段抬高型心肌梗死(STEMI)急诊经皮冠状动脉介入(PCI)的心肌保护作用。方法单中心、前瞻性、随机对照研究。连续纳入2018年1月至2021年9月在新乡医学院附属焦作市人民医院心内科病房接受PCI治疗的STEMI患者208例。按随机数字表法分为4组:A组(52例):常规PCI;B组(52例):RIPostC+常规PCI;C组(52例):尼可地尔+常规PCI;D组(52例):RIPostC+尼可地尔+常规PCI。于PCI术前后检测心肌灌注、心律失常、炎症反应、血管内皮功能、心肌损伤及心功能指标;记录术后12个月内主要不良心血管事件(MACE,包括再发心肌梗死、再发心力衰竭、心原性休克和心原性死亡)。结果(1)D组PCI术后即刻校正的TIMI血流帧数计数(CTFC)、术后24 h Curtis-Walker评分及恶性心律失常发生率均低于A组,术后2 h ST段回落幅度高于A组(均为P<0.01);(2)PCI术后48 h,D组的高敏C反应蛋白(hs-CRP)、白细胞介素6(IL-6)、丙二醛(MDA)和血管内皮生长因子(VEGF)水平均低于A、B和C组,超氧化物歧化酶(SOD)和一氧化氮(NO)水平均高于A、B和C组(均为P<0.001);B、C组的hs-CRP、IL-6、MDA和VEGF水平均低于A组,SOD和NO水平均高于A组(均为P<0.001);(3)PCI术后12 h和48 h,D组的高敏心肌肌钙蛋白I(hs-cTnI)水平均低于A、B和C组,B、C组的hs-cTnI水平均低于A组(均为P<0.001);(4)PCI术后1个月和12个月,D组的左心室射血分数(LVEF)水平均高于A、B和C组,B、C组的LVEF水平均高于A组(均为P<0.001);(5)PCI术后12个月内,4组患者的MACE发生率无统计学差异(χ^(2)=4.396,P=0.22)。结论单纯尼可地尔或RIPostC在PCI中均具有改善心肌灌注、拮抗氧化应激、抑制炎症反应、改善血管内皮、保护心肌细胞和改善心功能等作用,尼可地尔联合RIPostC的心肌保护作用明显优于单纯尼可地尔或RIPostC,联用具有协同、叠加效果。
